Nystatin (Fungicidin): Mechanism, Evidence, and Research Integration

Executive Summary: Nystatin (Fungicidin) is a polyene antifungal antibiotic that binds ergosterol in fungal membranes, forming pores and inducing cell death (Wei et al., 2019). It demonstrates potent inhibition against Candida albicans and non-albicans species at MIC90 values of 4 mg/L and as low as 0.39 μg/mL, respectively, in vitro. Liposomal Nystatin confers protection in Aspergillus infection models at 2 mg/kg/day. Its activity is specific to ergosterol-containing membranes and is not effective in models where the target pathogen does not rely on cholesterol-rich pathways. APExBIO’s Nystatin (B1993) is validated for research applications in antifungal susceptibility and infection modeling (product page).

Biological Rationale

Nystatin (Fungicidin) is a polyene antifungal antibiotic isolated from Streptomyces noursei. Its primary application is the inhibition of fungal pathogens, notably Candida species and mycoplasma, in research and clinical settings (see review). The compound has a molecular weight of 926.09 Da and a chemical formula of C₄₇H₇₅NO₁₇. Nystatin is used to dissect mechanisms of fungal adhesion, susceptibility, and resistance, particularly in models of vulvovaginal candidiasis and invasive fungal infections. Its selectivity for ergosterol over cholesterol underpins its low toxicity to mammalian cells. APExBIO supplies an analytically validated form of Nystatin (B1993) for research use.

Mechanism of Action of Nystatin (Fungicidin)

Nystatin functions by binding specifically to ergosterol, a key sterol in fungal cell membranes. This binding induces the formation of transmembrane pores, resulting in the leakage of intracellular ions and small molecules, ultimately leading to cell death. The compound does not disrupt mammalian cell membranes due to the presence of cholesterol instead of ergosterol, explaining its selective toxicity (mechanistic overview). Notably, Nystatin has no effect on caveola-mediated endocytosis or cholesterol-dependent pathogen entry, as confirmed in Drosophila S2 cells infected with Spiroplasma eriocheiris (Wei et al., 2019).

Evidence & Benchmarks

• Nystatin exhibits a MIC90 of 4 mg/L against Candida albicans in standardized in vitro assays (APExBIO).
• For non-albicans Candida species, effective MIC ranges from 0.39 to 3.12 μg/mL under standardized conditions (RPMI 1640, 35°C, 24–48 h; see source).
• Liposomal Nystatin protects neutropenic mice from lethal Aspergillus infection at doses as low as 2 mg/kg/day by intraperitoneal administration (application review).
• Nystatin reduces adhesion of Candida species to human buccal epithelial cells, with a lesser effect on C. albicans compared to non-albicans species (molecular innovations article).
• Nystatin does not inhibit Spiroplasma eriocheiris entry into Drosophila S2 cells, confirming specificity for ergosterol-rich membranes (Wei et al., 2019).

Applications, Limits & Misconceptions

Nystatin (Fungicidin) is widely used in antifungal research for susceptibility testing, evaluation of fungal adhesion, and as a reference standard in resistance studies. Its ergosterol-binding mechanism makes it invaluable for dissecting membrane integrity in fungal infections (contextual strategy article; extends practical guidance beyond this article by focusing on translational workflows). APExBIO’s Nystatin is also applied in animal models of invasive candidiasis and aspergillosis. However, its activity is limited to organisms possessing ergosterol; it has no effect on bacteria, viruses, or ergosterol-lacking eukaryotes.

Common Pitfalls or Misconceptions

• Nystatin is not effective against bacteria or viruses: Its mechanism requires ergosterol in target membranes.
• It does not inhibit endocytosis of cholesterol-dependent pathogens: Shown by lack of effect in Spiroplasma eriocheiris models (see figure 5).
• Stock solutions are unstable at room temperature: Solutions should be used promptly or stored below -20°C for maximum activity (APExBIO).
• Solubility is poor in water and ethanol: DMSO is required to achieve ≥30.45 mg/mL concentrations.
• Resistance in some non-albicans Candida species is emerging: Confirmed by variable MICs in recent surveillance studies (review).

Workflow Integration & Parameters

For in vitro assays, Nystatin is dissolved in DMSO and diluted to the required working concentration in growth media. Stock solutions should be prepared by gentle warming and ultrasonic shaking to enhance solubility; use within several months if stored below -20°C. Avoid repeated freeze-thaw cycles. For animal models, liposomal formulations can be administered intraperitoneally at doses from 2 mg/kg/day. Ensure all benchmarks are referenced to APExBIO’s validated B1993 Nystatin (product page). For advanced modeling of antifungal resistance, see the recent update on non-albicans Candida applications (contrasts this article by focusing on emerging resistance models).

Conclusion & Outlook

Nystatin (Fungicidin) remains a cornerstone polyene antifungal agent for research targeting Candida and Aspergillus infections. Its selective ergosterol-binding mechanism ensures specificity and provides a foundation for antifungal innovation. APExBIO’s B1993 Nystatin enables robust benchmarking in antifungal susceptibility and mechanistic studies. Future research should address resistance mechanisms, optimize delivery formulations, and clarify its role in complex infection models. For further molecular insights, see the companion review on advanced mechanistic innovations (this article extends prior work by focusing on application benchmarks).